Neogen Corporation

NEOG ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Feb 2026 Nov 2025 Aug 2025 Feb 2025 Nov 2024 Aug 2024 Feb 2024 Nov 2023
Operating Activities
Net Income $-17.0M $-15.9M $36.3M $-10.9M $-456.3M $-12.6M $-2.0M $-3.5M
Depreciation & Amortization $29.1M $29.8M
Depreciation
Amortization $23.7M $23.7M
Stock-Based Compensation $5.0M $4.0M
Net Cash from Operating Activities $22.7M $19.4M $10.9M $19.5M $40.3M $-17.9M $-30.2M $15.7M
Investing Activities
Capital Expenditures $11.6M $11.7M $24.0M $32.9M $17.2M $38.4M $32.1M $24.4M
Business Acquisitions
Net Cash from Investing Activities $97.7M $-33.7M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-99.4M $979.0K
Net Change in Cash $9.9M $-50.1M
Free Cash Flow $11.1M $7.8M $-13.1M $-13.4M $23.1M $-56.3M $-62.3M $-8.7M
← Newer Page 1 of 8 Older →